RT Journal Article
SR Electronic
T1 Neurosarcoidosis
JF Neurology - Neuroimmunology Neuroinflammation
JO Neurol Neuroimmunol Neuroinflamm
FD Lippincott Williams & Wilkins
SP e1084
DO 10.1212/NXI.0000000000001084
VO 8
IS 6
A1 Michael J. Bradshaw
A1 Siddharama Pawate
A1 Laura L. Koth
A1 Tracey A. Cho
A1 Jeffrey M. Gelfand
YR 2021
UL http://nn.neurology.org/content/8/6/e1084.abstract
AB Although often regarded as a protean illness with myriad clinical and imaging manifestations, neurosarcoidosis typically presents as recognizable syndromes that can be approached in a rational, systematic fashion. Understanding of neurosarcoidosis has progressed significantly in recent years, including updated diagnostic criteria and advances in treatment. The diagnosis of neurosarcoidosis is established by the clinical syndrome, imaging and histopathological findings, and exclusion of other causes. Mounting evidence supports the use of tumor necrosis factor inhibitors as an important addition to the therapeutic armamentarium, along with glucocorticoids and steroid-sparing cytotoxic immunosuppressants. In this narrative review, we summarize recent advances in the diagnosis and treatment of neurosarcoidosis.ACE=angiotensin-converting enzyme; FDG=fluorodeoxyglucose; IgG=immunoglobulin G; LETM=longitudinally extensive myelitis; PNS=peripheral nervous system; TNF=tumor necrosis factor